XC243
Phase 2Small molecule
XC243 is one of 18 small molecule programs targeting Cystitis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Cystitis
#DrugCompanyPhaseTrials
1Ivadantin
PProcter and Gamble
Approved
Monurol
MMeitheal
Approved
Oxytrol
WWim Janssens
Approved
Advil
KKenvue Brands
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Elmiron
WWim Janssens
Phase 3
Raphamin
MMateria Medica Holding
Phase 3
Gynoflor
MMahidol University
Phase 3
Sodium Hyaluronate
SanofiPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XC243. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPHARMENTERPRISES LLC